Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

26.22 -1.50 (-5.41%)
Streaming Delayed Price Updated: 2:12 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now
These players have had their ups and downs -- but the future looks bright. 
Via The Motley Fool
Wall Street Eyes Strong Finish To The Week Despite Futures Suggesting Moderation In Tech Buying: Strategist Cautions Against Factoring Rapid, Steep Cuts Ahead Of Next Week's Fed Meeting
Now that the twin inflation reports are in the rearview mirror, U.S. stocks are hanging onto the slender optimism as traders look ahead to the Federal Reserve’s rate-setting meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
Moderna announced plans to slash its R&D budget by $1.1 billion by 2027. 
Via Talk Markets
Why Are Novavax Shares Trading Lower Today?
Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you need to know. 
Via Benzinga
Stocks Edge Up As Producer Inflation Supports Rate Cut Bets, Small Caps, Miners Rally: What's Driving Markets Thursday?
At midday on Thursday, Wall Street was showing slight gains, with small caps leading the charge. The Russell 2000 index surged 1.2%, outperforming large-cap indices in a notable rebound. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Moderna R&D Day Highlights Progress and Strategic Priorities
Via ACCESSWIRE
Check Out What Whales Are Doing With MRNA
Via Benzinga
Moderna Outlines Post-Covid Roadmap, Cuts Research Budget, Forecasts 2025 Sales Below Expectations
Moderna highlights its mRNA pipeline and financial strategy at R&D Day and aims for 10 product approvals by 2027, expects to reduce R&D spending by $1.1 billion, and projects profitability for its... 
Via Benzinga
Nasdaq, S&P 500 Set For Modest Gains As Investors Eye August Inflation Data And ECB Rate Decision
U.S. stocks could open Thursday’s session modestly higher after the remarkable recovery they staged in the previous session. The spotlight is on the producer price inflation report for August as... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Moderna To Slash $1.1 Billion From R&D Spending In Major Commercial Push
The company says it's investment in R&D has paid off. Now, it needs to move its focus to launching new products. 
Via Investor's Business Daily
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
An investment in these players today could score a big win down the road. 
Via The Motley Fool
A Closer Look at Moderna's Options Market Dynamics
Via Benzinga
Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Via ACCESSWIRE
Smart Money Is Betting Big In MRNA Options
Via Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV... 
Via Benzinga
Is Hims & Hers Health the Next Teladoc?
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. 
Via The Motley Fool
Exposures COVID-19
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Wall Street Rallies After Last Week's Sell-Off, Palantir Soars On S&P 500 Inclusion, Airlines Rally: What's Driving Markets Monday?
U.S. stocks started the new week with strong gains, as all major indices and sectors in the S&P 500 were in the green by midday in New York. This comes after Wall Street experienced its worst week of... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Moderna Stock Trading Higher On Monday?
Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu... 
Via Benzinga
Exposures COVID-19
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences. 
Via Benzinga
Is It Time to Buy August's Worst-Performing Nasdaq Stocks?
These tech stocks got hit hard last month. Should you buy the dip? 
Via The Motley Fool
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys. 
Via Benzinga
Jim Cramer: Oklo Is Losing Money 'Hand-Over-Fist,' But This Private Equity Stock Is A Buy
The "Mad Money" host said Oklo Inc. is a company that is again losing so much money "I can't even look at it." 
Via Benzinga
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Via ACCESSWIRE
Moderna, Inc. Shareholders - Robbins LLP Reminds MRNA Stockholders of the Class Action Lawsuit Against the Company – Seek Counsel Today
From Robbins LLP
Via GlobeNewswire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
Is It Time to Buy August's Worst-Performing S&P 500 Stocks?
What happened to August's worst-performing stocks? Discover if these underperformers from the famous S&P 500 index are potential buys or value traps. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.